The initial success of Sildenafil undeniably transformed the pharmaceutical landscape, but investing in companies heavily reliant on unbranded versions presents a challenging picture. Although early profits were significant, the cessation of patents and the rise of cheaper alternatives have diminished the customer base. Consequently, a thorough eva